Episode

Episode 189 - Cameron Pitt - Co-founder & COO Quanta Therapeutics

Podcast
The BioHub - by Avetix
Published
Jun 15, 2026
Duration seconds
1239
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-189---Cameron-Pitt---Co-founder--COO-Quanta-Therapeutics-e3kqi94
Audio
https://anchor.fm/s/f0076084/podcast/play/121505508/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-15%2F426177111-44100-2-98ca66e00371e.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-189-cameron-pitt-co-founder-coo-quanta-therapeutics
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-189-cameron-pitt-co-founder-coo-quanta-therapeutics.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-189-cameron-pitt-co-founder-coo-quanta-therapeutics/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-189-cameron-pitt-co-founder-coo-quanta-therapeutics.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of The BioHub Podcast, Max sits down with Cameron Pitt, Co-Founder and COO of Quanta Therapeutics. Cameron's career has taken him from academic research at Stanford and UCSF, to venture investing at Versant Ventures and Sofinnova Investments, before helping form and build Quanta Therapeutics from the ground up. Quanta is focused on one of the biggest challenges in oncology: targeting RAS-driven cancers. Using a novel approach designed to restore control of RAS signalling, the company is developing therapies aimed at addressing a broad range of RAS-driven tumours. In this conversation, we discuss Cameron's transition from academia to venture capital and company building, the science behind Quanta, the realities of building a biotech company, and how the team is thinking about growth and fundraising in today's market.